期刊文献+

高效液相色谱法测定人血浆中奥美拉唑浓度 被引量:6

Determination of Omeprazole in Human Plasma by HPLC
下载PDF
导出
摘要 建立测定人血浆中奥美拉唑浓度的高效液相色谱法,并应用于人体药代动力学研究。血浆样品中加入内标非那西丁后用乙酸乙酯提取,色谱柱为Zorbax SB—C18柱,流动相为0.05mol·L^-1乙酸铵溶液(用氨水调至pH7.0)-乙腈(68:32),流速为1.0ml·min^-1,紫外检测波长302nm。血浆中内源性物质对样品测定无干扰。本方法线性范围为0.01~2μg·ml^-1(r=0.9997),最低定量浓度为0.01μg·ml^-1,提取回收率大于80%,方法回收率为98.6%~103.1%,日内、日间RSD均小于6%。本法简便、准确,适用于奥美拉唑药代动力学的研究。 A HPLC method for the determination of omeprazole in human plasma was established, and was used on the research of pharmacokinetics in healthy volunteers. After addition of phenacetin ( internal standard), plasma samples was extracted with ethyl acetate and determined. A Zorbax SB - C18 column was used with the mobile phase of 0. 05mol·L^-1 ammonium acetate solution adjusted to pH 7.0 with concentrated ammonia) and acetonitrile (68: 32) with a flow rate of 1.0ml ·mol-1 The detection wavelength was at 302nm. The blank plasma did not interfere with the determination. The calibranon range was 0. 01 -2 μg·ml^-1 (r =0. 9997 ), and the quantitative limit was 0. 01 μg·ml^-1. The extraction recovery was more than 80%, and the method recovery was 98.6% - 103. 1%. RSD of within - day and between - day were less than 6%. The method is simple and accurate, and suitable for the pharmacokinetic study of omeprazole.
出处 《中国药事》 CAS 2006年第12期759-761,共3页 Chinese Pharmaceutical Affairs
关键词 奥美拉唑 高效液相色谱法 药代动力学 omeprazole pharmacokinetics HPLC
  • 相关文献

参考文献9

二级参考文献33

  • 1朱秀英,顾同进.奥美拉唑与法莫替丁治疗十二指肠溃疡的对比[J].新药与临床,1994,13(4):211-212. 被引量:9
  • 2楼雅卿,赵莉,张远.中国健康志愿者的奥美拉唑及其代谢物的药代动力学研究[J].中国临床药理学杂志,1994,10(1):14-21. 被引量:27
  • 3邓子煜,李雪宁,陈秋潮.HPLC测定奥美拉唑血药浓度[J].中国药学杂志,1996,31(10):608-610. 被引量:14
  • 4[1]Stephen PC, Deborah CR. Omeprazole: a preliminary review of its pharmacodynamic and pharnacokinetic properties, and theraputic potenial in peptic ulcer disease and Zollinger-Ellison syndrome[J].Drugs, 1986, 32:15
  • 5[2]Shim SH, Bok SJ, Kwon KI. Determination of omeprazole in rat plasma by HPLC with column switching [J]. Arch Pharm Res,1994, 17(6): 458
  • 6[3]Kang WK,Kim DS,Kwon KI. Advanced method for determination of omeprazole in plasma by HPLC[J]. Arch Pharm Res, 1999, 22(1):86
  • 7[4]Prichard PJ, Yoemans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage[J]. Gastroeterology, 1988(b), 88:64
  • 8[6]ANDERSSON T,BERGSTRAND R,CEDERBERG C.Influence of acid secretory status on absorption of omeprazole from enteric coated granules[J].Br J Clin Pharmacol,1991,31(3):275-278.
  • 9[7]ANDERSSON T,ANDREN K,CEDERBERG C,et al.Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects[J].Br J Pharmacal.1990,29(5),557-663.
  • 10[1]de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22):15419-15422.

共引文献80

同被引文献35

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部